Dr. Ravandi on Relapse/Refractory AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).
Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, chief, Section of Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).
Ravandi says the outcomes for patients with this disease are currently poor. Studies have looked at the population of cells in these patients, and there are certain complexities, such as clonal evolution and clonal selection, which make patients less amenable to traditional cytotoxins.
Ravandi believes that the treatment paradigm will move away from giving patients high doses of cytotoxins, with the exception of those who have a very long first remission duration. He adds that he and his colleagues will incorporate novel agents, in order to discover better strategies.
In order to prevent relapse/refractory AML, monitoring minimal residual disease, as well as eradicating it, becomes significant, concludes Ravandi.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
